

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Latifa DAHRICORREIA et al.) Group Art Unit:
Serial No:) Examiner:
Filed:) Attorney Docket No: 7594-83879
(SGcsbF1228/3 US)
For: PHARMACEUTICAL COMPOSITIONS)
WITH WOUND HEALING OR ANTI-)
COMPLEMENTARY ACTIVITY)
COMPRISING A DEXTRAN)
DERIVATIVE)

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified U.S. patent application as follows:

In the Claims

Please amend claims 5-7, 10, 11, and 14 as follows:

--5. (Amended) The use as claimed in claim 3 [or claim 4], characterized in that said pharmaceutical composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.

6. (Amended) The use as claimed in claim 3 [any one of claims 3 to 5], characterized in that said dextran derivative is enclosed in a vector.

7. (Amended) The use as claimed in claim 3 [any one of claims 3 to 6], characterized in that said pharmaceutical composition is adapted for oral administration.

10. (Amended) The use as claimed in claim 8 [or claim 9], characterized in that said pharmaceutical composition is present in the form of a gel, an ointment or an isotonic solution.

11. (Amended) The use as claimed in claim 8 [any one of claims 8 to 10], characterized in that said pharmaceutical composition is adapted to administration by local external application or by the parenteral route.

14. (Amended) The use as claimed in claim 12 [or claim 13], characterized in that said pharmaceutical composition is present in the form of eye drops or an ophthalmic ointment.--

Correspondence Address

All future correspondence concerning the above-identified U.S. patent application should be addressed to the undersigned attorney at the following address:

Thomas W. Tolpin
Welsh & Katz, Ltd.
22nd Floor
120 South Riverside Plaza
Chicago, IL 60606
Phone: (312) 655-1500
Fax: (312) 655-1501

Remarks

Reconsideration of the subject U.S. patent application in light of the present Amendment and Remarks is respectfully requested.

Authorization is hereby given to charge any deficiency in fees or any other fees in connection with the subject patent application to our Deposit Account No. 23-0920.

Claims 5-7, 10, 11, and 14 have been amended to avoid multiple dependency and better conform to U.S. practice.

A clean version of the entire set of pending claims is enclosed in accordance with 37 CFR 1.121 (c) (3).

The correspondence address has been updated.

Examination and allowance of the U.S. patent application with the pending claims as amended is respectfully requested.

Respectfully submitted,

Thomas W. Tolpin

Thomas W. Tolpin

Registration Number 27,600

Attorney for Applicants

Address:

Welsh & Katz, Ltd.
22nd Floor
120 South Riverside Plaza
Chicago, IL 60606
Phone: (312) 655-1500

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Latifa DAHRICORREIA et al.) Group Art Unit:
Serial No:) Examiner:
Filed:) Attorney Docket No: 7594-83879
(SGcsbF1228/3 US)
For: PHARMACEUTICAL COMPOSITIONS)
WITH WOUND HEALING OR ANTI-)
COMPLEMENTARY ACTIVITY)
COMPRISING A DEXTRAN)
DERIVATIVE)

CLEAN VERSION OF ENTIRE SET OF PENDING CLAIMS

A clean version of the entire set of pending claims is enclosed in accordance with 37 CFR 1.121 (c) (3).

Each claim of the clean version of the entire set of claims begins on a separate page in order to facilitate optical scanning of the claims by the U.S. Patent and Trademark Office.

1. A pharmaceutical composition which has a healing action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, preferably consisting of linked glucoside units,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient, with said dextran derivative being present at a unit dose of between 0.1 and 50 mg.

2. The use of the pharmaceutical composition as claimed in claim 1 for preparing a medicament having a healing action.

3. The use of the pharmaceutical composition as claimed in claim 1 for preparing a medicament having an action on the healing of the gastric mucosa.

4. The use as claimed in claim 3, characterized in that the unit dose of said dextran derivative is between 1.5 and 10 mg.

5. (Amended) The use as claimed in claim 3, characterized in that said pharmaceutical composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.

6. (Amended) The use as claimed in claim 3, characterized in that said dextran derivative is enclosed in a vector.

7. (Amended) The use as claimed in claim 3, characterized in that said pharmaceutical composition is adapted for oral administration.

8. The use of the pharmaceutical composition as claimed in claim 1 for preparing a medicament having an action on muscle healing.

9. The use as claimed in claim 8, characterized in that the unit dose of said dextran derivative is between 0.5 and 50 mg.

10. (Amended) The use as claimed in claim 8, characterized in that said pharmaceutical composition is present in the form of a gel, an ointment or an isotonic solution.

11. (Amended) The use as claimed in claim 8, characterized in that said pharmaceutical composition is adapted to administration by local external application or by the parenteral route.

12. The use of the pharmaceutical composition as claimed in claim 1 for preparing a medicament having an action on ocular healing.

13. The use as claimed in claim 12, characterized in that the unit dose of said dextran derivative is between 0.1 and 10 mg.

14. (Amended) The use as claimed in claim 12, characterized in that said pharmaceutical composition is present in the form of eye drops or an ophthalmic ointment.

15. A pharmaceutical composition which has an action on skin healing, which is adapted to topical administration and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, preferably consisting of linked glucoside units,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a concentration of less than 10% (by weight/volume).

16. The use of the pharmaceutical composition as claimed in claim 15 for preparing a medicament which has an action on skin healing and which is intended to be administered topically.

17. The use as claimed in claim 16, characterized in that said pharmaceutical composition is present in the form of a paste, an ointment, an aqueous liquid, an oily liquid, an aqueous gel, an oily gel, an aerosol, a foam, a microemulsion, a multiple emulsion, liposomes or nanoparticles.

18. A pharmaceutical composition which has an anticomplementary action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, preferably consisting of linked glucoside units,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.3 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.4,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a unit dose of between 5 and 30 mg.

19. The use of the pharmaceutical composition as claimed in claim 18 for preparing a medicament having an anticomplementary action.

20. The use as claimed in claim 19, characterized in that said pharmaceutical composition is present in the form of an isotonic solution.

21. A dressing, characterized in that it is soaked with the pharmaceutical composition as claimed in claim 15.